A subject in a clinical research trial experiences a serious unanticipated adverse drug experience. How should the investigator proceed with respect to the IRB after the discovery of the adverse event occurrence?A. Do not report the adverse drug experience to the IRB since it is a common adverse experience.B. Report the adverse drug experience to the IRB only if there are several other occurrences.C. Report the adverse drug experience as part of the continuing review report.D. Report the adverse drug experience in a timely manner in keeping with the IRB's policies and procedures using the forms or the mechanism provided by the IRB.

Quesiton : A subject in a clinical research trial experiences a serious unanticipated adverse drug experience. How should the investigator proceed with respect to the IRB after the discovery of the adverse event occurrence?A. Do not report the adverse drug experience to the IRB since it is a common adverse experience.B. Report the adverse drug experience to the IRB only if there are several other occurrences.C. Report the adverse drug experience as part of the continuing review report.D. Report the adverse drug experience in a timely manner in keeping with the IRB's policies and procedures using the forms or the mechanism provided by the IRB.

Answer: D. Report the adverse drug experience in a timely manner in keeping with the IRB's policies and procedures using the forms or the mechanism provided by the IRB.

A subject in a clinical research trial experiences a serious unanticipated adverse drug experience. How should the investigator proceed with respect to the IRB after the discovery of the adverse event occurrence?A. Do not report the adverse drug experience to the IRB since it is a common adverse experience.B. Report the adverse drug experience to the IRB only if there are several other occurrences.C. Report the adverse drug experience as part of the continuing review report.D. Report the adverse drug experience in a timely manner in keeping with the IRB's policies and procedures using the forms or the mechanism provided by the IRB. A subject in a clinical research trial experiences a serious unanticipated adverse drug experience . How should the investigator proceed with respect to the IRB after the discovery of the adverse event occurrence? A . Do not report the adverse drug experience to the IRB since it is a common adverse experience . A subject in a clinical research trial experiences a serious unanticipated adverse drug experience . How should the investigator proceed with respect to the IRB after the discovery of the adverse event occurrence? ... Report the adverse drug experience in a timely manner in keeping with the IRB' s policies and procedures using the forms or ... B. Report the adverse drug experience to the IRB only if there are several other occurrences. C . Report the adverse drug experience as part of the continuing review report. D . Report the adverse drug experience in a timely manner in keeping with the IRB' s policies and procedures using the forms or the mechanism provided by the IRB. Tue Apr 15 2014 00:00:00 GMT+0530 (IST) · Quiz Results - Basic Institutional Review Board (IRB) Regulations and Review Process You correctly answered 3 of 5 and received 3 of 5 possible points. Scroll down to review the quiz questions and the explanation of the answers. Question 1 Question : | A subject in a clinical research trial ... How should the investigator proceed with respect to the IRB after the discovery of the adverse event occurrence? Subscribe to view the full document. Report the adverse drug experience in a timely manner in keeping with the IRB' s policies and procedures using the forms or the mechanism provided by the IRB. Mon Jan 19 2015 00:00:00 GMT+0530 (IST) · Question 1 Question : A subject in a clinical research trial experiences a serious unanticipated adverse drug experience . How should the investigator proceed with respect to the IRB after the discovery of the adverse event occurrence? Your answer : Report the adverse drug experience as part of the continuing review report . The HHS regulations at 45 CFR part 46 do not define or use the term adverse event nor is there a common definition of this term across ... (Modified from the definition of serious adverse drug experience in FDA regulations at 21 CFR 312.32(a).) ... At the time of continuing review the IRB should ensure that the criteria for IRB approval under ... Within 30 days of the IRB’s receipt of the report of the UP from the investigator . IRB. ... - NHLBI Adverse Event and Unanticipated Problem Reporting Policy. 1. Q: Does this NHLBI policy only apply to clinical trials? ... But it’s difficult for an investigator to attribute a serious adverse event to a drug on the basis of an isolated ... written IND safety report of “any adverse experience associated with the use of the drug that is both serious and unexpected” and “any finding from tests in laboratory animals • Report promptly to the IRB all unanticipated problems involving risks to human subjects or others – Serious and Unexpected Suspected Adverse Reactions [56.108(b)(1); 312.53(c)(1)(vii); 312.66] • Immediately report to the sponsor any serious adverse event whether or not considered drug related